The effect of proton pump inhibitors on fracture risk: Report from the Canadian Multicenter Osteoporosis Study

Osteoporosis International

Volumn 24, Issue 4, 2013, Pages 1161-1168

  Fraser, L A ^a,d   Leslie, W D ^b   Targownik, L E ^b   Papaioannou, A ^c   Adachi, J D ^c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d ST JOSEPH S HEALTH CENTRE   (Canada)

Author keywords

Fracture; Osteoporosis; Proton pump inhibitors; Risk factor

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CORTICOSTEROID; ESOMEPRAZOLE; ETIDRONIC ACID; LANSOPRAZOLE; OMEPRAZOLE; PAMIDRONIC ACID; PANTOPRAZOLE; RABEPRAZOLE; RISEDRONIC ACID; ZOLEDRONIC ACID;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; BONE DENSITY; COHORT ANALYSIS; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; EXERCISE; FEMALE; FEMUR NECK; FOLLOW UP; FRAGILITY FRACTURE; HIGH RISK POPULATION; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT MONITORING; PHYSICAL ACTIVITY; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM;

AGED; BONE DENSITY; CANADA; DRUG UTILIZATION; FEMALE; FEMUR NECK; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OSTEOPOROTIC FRACTURES; PROTON PUMP INHIBITORS; RISK FACTORS;

EID: 84876466976     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-012-2112-9     Document Type: Article

References (41)

1. Berger C, Goltzman D, Langsetmo L, Joseph L, Kreiger N, Tenenhouse A et al (2010) Peak bone mass from longitudinal data: implications for the prevalence, pathophysiology, and diagnosis of osteoporosis. J Bone Miner Res 25:1948-1957
2. Papaioannou A, Kennedy CC, Ioannidis G, Sawka A, Hopman WM, Pickard L et al (2009) The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study. Osteoporos Int 20:703-714
3. Adachi JD, Loannidis G, Berger C, Joseph L, Papaioannou A, Pickard L et al (2001) The influences of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int 12:903-908
4. Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 301:513-521
5. Becker DJ, Kilgore ML, Morrisey MA (2010) The societal burden of osteoporosis. Curr Rheumatol Rep 12:186-191
6. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993-1000
7. Richards JB, Papaioannou A, Adachi JD, Joseph L, Whitson HE, Prior JC et al (2007) Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 167:188-194
8. Jetté N, Lix LM, Metge CJ, Prior HJ, McChesney J, Leslie WD (2011) Association of antiepileptic drugs with nontraumatic fractures: a population-based analysis. Arch Neurol 68:107-112
9. Mazziotti G, Canalis E, Giustina A (2010) Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med 123:877-884
10. Yu EW, Bauer SR, Bain PA, Bauer DC (2011) Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med 124:519-526
11. U.S. Food and Drug Administration (2011). FDA Drug Safety Communication. possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. Accessed at http://www.fda.gov/drugs/drugsafety/ postmarketdrugsafetyinformationforpateintsandproviders/ucm213206.htm on July 1, 2011.
12. Heidelbaugh JJ, Goldberg KL, Inadomi JM (2009) Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk. Am J Gastroenterol 104(Suppl 2):27-32
13. Katz MH (2010) Failing the acid test: benefits of proton pump inhibitors may not justify the risks for many users. Arch Intern Med 170:747-748
14. Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M et al (2010) Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 170:784-790
15. Hoorn EJ, van der Hoek J, de Man RA, Kuipers EJ, Bolwerk C, Zietse R (2010) A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis 56:112-116
16. Lin SL, Chang HM, Liu CP, Chou LP, Chan JW (2011) Clinical evidence of interaction between clopidogrel and proton pump inhibitors. World J Cardiol 3:153-164
17. Sheen E, Triadafilopoulos G (2011) Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci 56:931-950
18. Kaye JA, Jick H (2008) Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 28:951-959
19. Targownik LE, Leslie WD (2011) The relationship among proton pump inhibitors, bone disease and fracture. Expert Opin Drug Saf 10:901-912
20. Kreiger N, Tenenhouse A, Joseph L, Mackenzie T, Poliquin S, Brown JP et al (1999) The Canadian Multicentre Osteoporosis Study (CaMos): background, rationale, methods. Can J Aging 18:376-387
21. Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417-427
22. Bessette L, Ste-Marie L-G, Jean S, Davison KS, Beaulieu M, Baranci M et al (2008) The care gap in diagnosis and treatment of women with a fragility fracture. Osteoporos Int 19:79-86
23. Fisher LD, Lin DY (1999) Time-dependent covariates in the cox proportional-hazards regression model. Annu Rev Public Health 20:145-157
24. Roux C, Briot K, Gossec L, Kolta S, Blenk T, Felsenberg D et al (2009) Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int 84:13-19
25. Roughead EE, McGeechan K, Sayer GP (2004) Bisphosphonate use and subsequent prescription of acid suppressants. Br J Clin Pharmacol 57:813-816
26. McGowan B, Bennett K, Barry M, Canny M (2008) The utilisation and expenditure of medicines for the prophylaxis and treatment of osteoporosis. Ir Med J 101:38-41
27. Pouwels S, Lalmohamed A, Souverein P, Cooper C, Veldt BJ, Leufkens HG et al (2011) Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporos Int 22(3):903-10
28. Yang YX, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 296:2947-2953
29. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD (2008) Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 179:319-326
30. Ensrud KE, Duong T, Cauley JA, Heaney RP, Wolf RL, Harris E et al (2000) Low fractional calcium absorption increases the risk for hip fracture in women with low calcium intake. Ann Intern Med 132:345-353
31. Bo-Linn GW, Davis GR, Buddrus DJ, Morawski SG, Santa Ana C, Fordtran JS (1984) An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Invest 73:640-647
32. Serfaty-Lacrosniere C, Wood RJ, Voytko D, Saltzman JR, Pedrosa M, Sepe TE et al (1995) Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr 14:364-368
33. Recker RR (1985) Calcium absorption and achlorhydria. N Engl J Med 313:70-73
34. O'Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ (2005) Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 118:778-781
35. McLean RR, Jacques PF, Selhub J, Tucker KL, Samelson EJ, Broe KE et al (2004) Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 350:2042-2049
36. Targownik LE, Lix LM, Leung S, Leslie WD (2010) Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology 138:896-904
37. Yu EW, Blackwell T, Ensrud KE, Hillier TA, Lane NE, Orwoll E et al (2008) Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int 83:251-259
38. Gray SL, LaCroix AZ, Larson J (2010) Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med 170:765-771
39. Targownik LE, Leslie WD, Davison S, Goltzmen D, Jamal S, Josse RG, et al Proton pump inhibitors are associated with decreased bone mineral density. Amer J Gastroenterol. 106(Suppl 2):405.
40. Mizunashi K, Furukawa Y, Katano K, Abe K (1993) Effect of omeprazole, an inhibitor of H+, K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int 53:21-25
41. Sheraly AR, Lickorish D, Sarraf F, Davies JE (2009) Use of gastrointestinal proton pump inhibitors to regulate osteoclast-mediated resorption of calcium phosphate cements in vivo. Curr Drug Deliv 6:192-198